Loading
A new regimen built around brentuximab vedotin cured more patients with advanced Hodgkin lymphoma than the intensive BEACOPP standard, and did so with less toxicity, including less damage to fertility.
International randomised phase 3 trial of 1,500 patients with newly diagnosed advanced-stage classical Hodgkin lymphoma comparing PET-guided BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone) with PET-guided escalated BEACOPP, four or six cycles depending on interim PET.
Four-year progression-free survival was 94.3 percent with BrECADD against 90.9 percent with escalated BEACOPP, and treatment-related morbidity was lower (about 42 versus 59 percent), with faster recovery of gonadal function. BrECADD is now the GHSG standard for advanced disease.
For fit younger patients treated in the intensive German tradition, BrECADD replaces escalated BEACOPP; how it compares with nivolumab-AVD from S1826 is the open question.
Shares PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, Dacarbazine, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares Dacarbazine, Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Doxorubicin.
Shares Dacarbazine, Etoposide, Doxorubicin, Cyclophosphamide.
Shares GHSG HD21, Dacarbazine, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Etoposide.
Shares Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Etoposide, Doxorubicin.
Shares GHSG HD21, PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, Brentuximab vedotin, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.
Shares GHSG HD21, PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Etoposide.
Shares GHSG HD21, Brentuximab vedotin, Advanced-stage classical Hodgkin lymphoma (stage III to IV), Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting.